120635-25-8
Chemical Structure
Mofegiline hydrochloride
Synonym(s): MDL72974A
- CAS No.: 120635-25-8
- Formula:C11H14ClF2N
- Molecular Weight:233.69
IUPAC Name: (E)-2-(fluoromethylene)-4-(4-fluorophenyl)butan-1-amine hydrochloride
InChIKey: QUCNNQHLIHGBIA-HCUGZAAXSA-N
SMILES: FC1=CC=C(CC/C(CN)=C(F)/[H])C=C1.[H]Cl
Biological Activity: Mofegiline hydrochloride (MDL-72974A) is an orally active and blood-brain barrier-penetrant MAO-B/SSAO selective inhibitor, with an IC50 of 3.6 nM for MAO-B and 10 nM for SSAO. Mofegiline hydrochloride is a cationic amphiphilic compound that can induce indirect sympathomimetic effects, lysosomal accumulation, hERG channel interactions, phospholipidosis, and cell death. Mofegiline hydrochloride protects mice from MPTP-induced depletion of striatal dopamine, DOPAC, and HVA. Mofegiline hydrochloride can be used in research related to Parkinson's disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mofegiline hydrochloride | 99.57% | Mofegiline hydrochloride (MDL-72974A) is an orally active and blood-brain barrier-penetrant MAO-B/SSAO selective inhibitor, with an IC50 of 3.6 nM for MAO-B and 10 nM for SSAO. Mofegiline hydrochloride is a cationic amphiphilic compound that can induce indirect sympathomimetic effects, lysosomal accumulation, hERG channel interactions, phospholipidosis, and cell death. Mofegiline hydrochloride protects mice from MPTP-induced depletion of striatal dopamine, DOPAC, and HVA. Mofegiline hydrochloride can be used in research related to Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zreika M, et al. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1989;1(4):243-54. [Content Brief]
- [2]. Fang J, et al. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology. 1994 Jun;33(6):763-8. [Content Brief]
- [3]. Dow J, et al. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Drug Metab Dispos. 1994 Sep-Oct;22(5):738-49. [Content Brief]
- [4]. Yu PH, et al. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species. Biochem Pharmacol. 1992 Jan 22;43(2):307-12. [Content Brief]
